Login to Your Account

Clinic Roundup

Wednesday, July 11, 2012
• OncoGenex Pharmaceuticals Inc., of Bothell, Wash., updated its clinical development plans for custirsen with details for a Phase III trial in non-small-cell lung cancer (NSCLC) to begin enrollment later this year. The open-label, 1,100-patient study will evaluate the potential survival benefit of combining custirsen with docetaxel in patients who have progressed after first-line treatment.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription